Heronova Pharmaceuticals
Clinical trials sponsored by Heronova Pharmaceuticals, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug for rare eye disease begins first human tests Results expected Dec 2026 (estimated)
-
A pill aimed at a specific gene flaw in Hard-to-Treat tumors
Disease control Recruiting nowResearchers are testing an experimental tablet called DC50292A in adults with advanced or metastatic solid tumors that have lost a gene called MTAP and have not responded to standard treatments. The trial has two parts: one to find a safe dose and another to give that dose to mor…
Phase 1 • Sponsor: Heronova Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill shrink Hard-to-Treat ovarian tumors?
Disease control Recruiting nowResearchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…
Phase 1/2 • Sponsor: Heronova Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug for rare eye disease begins first human tests
Knowledge-focused Recruiting nowThis early-phase trial tests the safety of an oral drug called DC6001 in 76 healthy adults. Researchers will give single or multiple doses to see how the body handles the drug and if it causes side effects. This study does not involve people with Stargardt disease and is not desi…
Phase 1 • Sponsor: Heronova Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC